These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 35253814)

  • 21. Visceral leishmaniasis affects liver and spleen concentrations of amphotericin B following administration to mice.
    Gershkovich P; Wasan EK; Sivak O; Li R; Zhu X; Werbovetz KA; Tidwell RR; Clement JG; Thornton SJ; Wasan KM
    J Antimicrob Chemother; 2010 Mar; 65(3):535-7. PubMed ID: 20026611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres.
    Sánchez-Brunete JA; Dea MA; Rama S; Bolás F; Alunda JM; Raposo R; Méndez MT; Torrado-Santiago S; Torrado JJ
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3246-52. PubMed ID: 15328080
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biodegradable functional polycarbonate micelles for controlled release of amphotericin B.
    Wang Y; Ke X; Voo ZX; Yap SSL; Yang C; Gao S; Liu S; Venkataraman S; Obuobi SAO; Khara JS; Yang YY; Ee PLR
    Acta Biomater; 2016 Dec; 46():211-220. PubMed ID: 27686042
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surface-engineered dendrimeric nanoconjugates for macrophage-targeted delivery of amphotericin B: formulation development and in vitro and in vivo evaluation.
    Jain K; Verma AK; Mishra PR; Jain NK
    Antimicrob Agents Chemother; 2015 May; 59(5):2479-87. PubMed ID: 25645852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Co-delivery of amphotericin B and pentamidine loaded niosomal gel for the treatment of
    Anjum A; Shabbir K; Din FU; Shafique S; Zaidi SS; Almari AH; Alqahtani T; Maryiam A; Moneeb Khan M; Al Fatease A; Bashir S; Khan GM
    Drug Deliv; 2023 Dec; 30(1):2173335. PubMed ID: 36722301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bovine serum albumin nanoparticles containing amphotericin B were effective in treating murine cutaneous leishmaniasis and reduced the drug toxicity.
    Casa DM; Scariot DB; Khalil NM; Nakamura CV; Mainardes RM
    Exp Parasitol; 2018 Sep; 192():12-18. PubMed ID: 30026113
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimizing efficacy of amphotericin B through nanomodification.
    Vyas SP; Gupta S
    Int J Nanomedicine; 2006; 1(4):417-32. PubMed ID: 17722276
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new nanoemulsion formulation improves antileishmanial activity and reduces toxicity of amphotericin B.
    Santos DCMD; de Souza MLS; Teixeira EM; Alves LL; Vilela JMC; Andrade M; Carvalho MDG; Fernandes AP; Ferreira LAM; Aguiar MMG
    J Drug Target; 2018 Apr; 26(4):357-364. PubMed ID: 29041824
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preparation and Characterization of Nanostructured Lipid Carriers for Improved Topical Drug Delivery: Evaluation in Cutaneous Leishmaniasis and Vaginal Candidiasis Animal Models.
    Riaz A; Hendricks S; Elbrink K; Guy C; Maes L; Ahmed N; Kiekens F; Khan GM
    AAPS PharmSciTech; 2020 Jul; 21(5):185. PubMed ID: 32632542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amphotericin B formulations: a comparative review of efficacy and toxicity.
    Hamill RJ
    Drugs; 2013 Jun; 73(9):919-34. PubMed ID: 23729001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exploitation of lectinized lipo-polymerosome encapsulated Amphotericin B to target macrophages for effective chemotherapy of visceral leishmaniasis.
    Gupta PK; Asthana S; Jaiswal AK; Kumar V; Verma AK; Shukla P; Dwivedi P; Dube A; Mishra PR
    Bioconjug Chem; 2014 Jun; 25(6):1091-102. PubMed ID: 24842628
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy of aerosol treatment with non-ionic surfactant vesicles containing amphotericin B in rodent models of leishmaniasis and pulmonary aspergillosis infection.
    Alsaadi M; Italia JL; Mullen AB; Ravi Kumar MN; Candlish AA; Williams RA; Shaw CD; Al Gawhari F; Coombs GH; Wiese M; Thomson AH; Puig-Sellart M; Wallace J; Sharp A; Wheeler L; Warn P; Carter KC
    J Control Release; 2012 Jun; 160(3):685-91. PubMed ID: 22516093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Formulation, characterization and in vitro anti-leishmanial evaluation of amphotericin B loaded solid lipid nanoparticles coated with vitamin B
    Singh A; Yadagiri G; Parvez S; Singh OP; Verma A; Sundar S; Mudavath SL
    Mater Sci Eng C Mater Biol Appl; 2020 Dec; 117():111279. PubMed ID: 32919641
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Self assembled ionically sodium alginate cross-linked amphotericin B encapsulated glycol chitosan stearate nanoparticles: applicability in better chemotherapy and non-toxic delivery in visceral leishmaniasis.
    Gupta PK; Jaiswal AK; Asthana S; Verma A; Kumar V; Shukla P; Dwivedi P; Dube A; Mishra PR
    Pharm Res; 2015 May; 32(5):1727-40. PubMed ID: 25425053
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhancing Safety and Efficacy by Altering the Toxic Aggregated State of Amphotericin B in Lipidic Nanoformulations.
    Das S; Devarajan PV
    Mol Pharm; 2020 Jun; 17(6):2186-2195. PubMed ID: 32324420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Formulation of Amphotericin B in PEGylated Liposomes for Improved Treatment of Cutaneous Leishmaniasis by Parenteral and Oral Routes.
    Ramos GS; Vallejos VMR; Borges GSM; Almeida RM; Alves IM; Aguiar MMG; Fernandes C; Guimarães PPG; Fujiwara RT; Loiseau PM; Ferreira LAM; Frézard F
    Pharmaceutics; 2022 May; 14(5):. PubMed ID: 35631575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Engineering Oral and Parenteral Amorphous Amphotericin B Formulations against Experimental Trypanosoma cruzi Infections.
    Rolón M; Serrano DR; Lalatsa A; de Pablo E; Torrado JJ; Ballesteros MP; Healy AM; Vega C; Coronel C; Bolás-Fernández F; Dea-Ayuela MA
    Mol Pharm; 2017 Apr; 14(4):1095-1106. PubMed ID: 28198632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and toxicity evaluation of new amphotericin B micelle systems for brain fungal infections.
    Moreno-Rodríguez AC; Torrado-Durán S; Molero G; García-Rodríguez JJ; Torrado-Santiago S
    Int J Pharm; 2015 Oct; 494(1):17-22. PubMed ID: 26256151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimization, stabilization, and characterization of amphotericin B loaded nanostructured lipid carriers for ocular drug delivery.
    Lakhani P; Patil A; Wu KW; Sweeney C; Tripathi S; Avula B; Taskar P; Khan S; Majumdar S
    Int J Pharm; 2019 Dec; 572():118771. PubMed ID: 31669555
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hemolytic and pharmacokinetic studies of liposomal and particulate amphotericin B formulations.
    Serrano DR; Hernández L; Fleire L; González-Alvarez I; Montoya A; Ballesteros MP; Dea-Ayuela MA; Miró G; Bolás-Fernández F; Torrado JJ
    Int J Pharm; 2013 Apr; 447(1-2):38-46. PubMed ID: 23438978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.